The prevalence of lupus anticoagulant in normal pregnancy and in women with recurrent fetal loss—recommendations for laboratory testing for lupus anticoagulant

Abdul Aziz A. Al-Mishari, MD, FRCOG*; Abdul Galil M. Abdel Gader, MD, PhD, FRCP†; Abdul Wahab Al-Jabbari, MD, FRCOG*; Abdul Karim M. Al-Momen, MD, FRCPc; Mohamed O. Gad El Rab, MD**; Zainab H. Babay, MD, ABOG*; Nasim Mahmoud, MD*

BACKGROUND: There is wide disagreement in the literature on the rate of detection of lupus anticoagulant (LA) in women with recurrent fetal loss (RFL). The aim of this study was to determine the prevalence of LA using four phospholipid-dependent coagulation tests in a large population of Saudi women.

PATIENTS AND METHODS: We determined the prevalence of LA in women with RFL (n=925), normal pregnancy (n=663), and in healthy blood donors (n=204), at the King Khalid University Hospital, Riyadh. The following coagulation tests were employed: the activated partial thromboplastin time (APTT), platelet neutralization procedure (PNP), kaolin clotting time (KCT) and the dilute Russel’s viper venom test (dRVT).

RESULTS: In RFL patients, positive APTT was 10.2%, APTT+PNP 3.6%, KCT 10.5%, and dRVT 10.9%. In normal pregnancy, the corresponding figures were 12.8%, 3.1%, 10.8%, and 5.6%. Three positive tests occurred in 2.3% of RFL patients, including APTT+KCT 3.5%, APTT+dRVT 3.9%, and KCT+dRVT 4.1%. The corresponding figures for normal pregnancy were 1.6% for three positive tests, and 3.0%, 1.8%, 2.4%, respectively. The dRVT was the only test that showed a rate of positive results almost double that seen in normal pregnancy.

CONCLUSIONS: If only one or even two screening tests were performed, a significant number of LA positive cases would have been missed. This could make a difference to treating physicians as to the possible etiology and management of RFL. It is therefore advisable to routinely use the three tests (APTT, KCT and dRVT) when screening for LA.

KEYWORDS: Antiphospholipid antibodies, lupus anticoagulant, RFL, pregnancy
This communication is part of a large project investigating the various etiological factors of RFL in Saudi Arabia.

**Patients and Methods**

Nine hundred and twenty-five (925) women with recurrent fetal loss (RFL) were recruited consecutively from a special outpatient RFL Clinic, King Khalid University Hospital, Riyadh. These women were subjected to a detailed interview and the information was collected in a specially designed form. They underwent a general medical examination and extensive laboratory and radiological tests. Only those with no proven systemic or local gynecological cause of RFL were included. These patients gave a history of recurrent abortions, ranging from 3 to 15. Their ages ranged from 19 to 40 years (mean ± SD, 29.9 ± 6.5); the majority of the women (67.5%) were in their peak reproductive age group (25-34 years). The blood samples for this study were collected when these women were non-pregnant and under investigation as to the possible etiological role of lupus anticoagulant in their RFL.

Six hundred and sixty-three (663) women with a trouble-free pregnancy were recruited from the antenatal clinic at King Khalid University Hospital, Riyadh. Their ages ranged from 14 to 45 years, (mean ± SD, 28.8 ± 6.1). These women were further subdivided according to gestational age (gestational age was calculated from the date of the last menstrual period in conjunction with the findings of an ultrasound scan) into three subgroups as follows: first trimester (n=132), second trimester (n=293), third trimester (n=238). Healthy controls (n = 204) were blood donors of both sexes.

Venous blood samples were collected in sodium citrate (0.11M) to give a blood citrate ratio of 9:1. Samples were transported without delay to the coagulation laboratory. A 15-minute double centrifugation at 3000 rpm was done before separating plasma by double centrifugation as follows: centrifugation of citrated blood at 3000 rpm for 15 min; a plastic transfer pipette was then used to remove the supernatant platelet rich plasma, which was placed in a second plastic tube and recentrifuged under identical conditions. The resulting platelet poor plasma (PPP) was either tested immediately or stored in aliquots in the frozen state at -40°C for testing at a later date.

Assay techniques for detecting lupus anticoagulant followed the guidelines of the Scientific and Standardisation Committee of the International Society for Thrombosis and Haemostasis (ISTH), with respect to both pre-analytical and analytical variables. An activated partial thromboplastin time (APTT) was performed using a sensitive APTT reagent (APTT Manchester Comparative Reagents - UK) according to the manufacturer's instructions. The clotting time was recorded in duplicates using a coagulometer (Amelung Coagulometer-KCA4A, Germany). The test is taken as positive if the patient's APTT is more than 2 SDs (3.5 sec) above the mean (48±7 seconds) of the normal range for healthy population, which is 55 (47±7 = 55 seconds). Mixing with normal pool plasma was undertaken in samples showing >5-second prolongation of the APTT and those who did not show a correction were tested further with the platelet neutralization procedure (PNP) (see below).

The Kaolin Clotting Time (KCT) was performed according to the method of Extner et al. An index of 10% or more is considered positive for the presence of LA. The Dilute Russel's Viper Venom Test (dRVVT) was performed according to the method of Thiagarajan et al. The venom (Manchester Comparative Reagents, UK) was reconstituted using Tris Buffered Saline, pH 7.5. The result is taken as positive for lupus anticoagulant if the index of patient clotting time divided by control plasma clotting time is >1.1. The Platelet Neutralization Procedure (PNP) was performed in conjunction with APTT. Shortening of the APTT by < 5 sec in the reaction mixture as compared to the saline control is considered confirmatory of positive for LA. The results of all tests were recorded in duplicates. These tests were done only once, when the patient presented the first time for investigation.

The Chi-square test was employed to determine the significance of differences in the prevalence of LA, based of the results of different laboratory tests. The prevalence of LA in normal pregnancy (Table 1) is shown for individual tests to facilitate the comparisons with other studies as well as those obtained in our RFL patients.

**Results**

When comparing the prevalence of LA between women with normal pregnancy or blood donors and those with RFL, dRVVT is the only test that showed a markedly higher prevalence of LA among women with RFL (10.9%) than normal pregnancy (5.6%; P<0.007), or healthy blood donors (1.2%; P<0.001). For RFL patients, the prevalence of LA was slightly higher for dRVVT (10.9%) when compared to the either the APTT (10.2%) or the KCT (10.5%), the values for any of the three tests being remarkably higher than in blood donors. For the combination of various screening tests, the prevalence of LA dropped markedly for both RFL patients as well as normal pregnancy, indicating that a patient who had a positive result for LA for one test will most probably have a negative result for the other two screening tests. Due to certain constraints, the PNP was employed only with the APTT and the results show that the prevalence of LA drops by approximately two thirds in both normal pregnant women and in patients with RFL, when the two tests are performed in those who were positive for APTT.

**Discussion**

The prevalence of lupus anticoagulant in normal pregnant women varies from 1.2% using the KCT test to 0.27% using the dRVVT and 0.11% when using the APTT.
Table 1. Prevalence of lupus anticoagulants in normal pregnancy and in women with recurrent fetal loss.

| Test               | Normal pregnancy (1st trimester) n=132 | Normal pregnancy (2nd trimester) n=293 | Normal pregnancy (3rd trimester) n=238 | Normal pregnancy (total) n=663 | Recurrent fetal loss n=925 | Blood donors n=204 | P value          | P value          |
|-------------------|----------------------------------------|----------------------------------------|----------------------------------------|-------------------------------|--------------------------|-------------------|-----------------|-----------------|
| APTT              | 10.6                                   | 13.4                                   | 12.6                                   | 12.8                          | 10.2                     | 3.0               | 0.001*          | 0.0043*         |
| APTT +PNP         | 3.8                                    | 2.4                                    | 1.3                                    | 3.1                           | 3.6                      | 0.0               | -              | -               |
| KCT               | 10.9                                   | 12.6                                   | 9.1                                    | 10.8                          | 10.5                     | 1.2               | 0.001*          | 0.0002          |
| dRVVT             | 6.8                                    | 4.8                                    | 5.2                                    | 5.6                           | 10.9                     | 1.2               | 0.0279*         | 0.001*          |
| 3 positive tests  | 1.5                                    | 1.7                                    | 0.0                                    | 1.6                           | 2.3                      | 0.0               | 0.1333          | 0.0603          |
| APTT +KCT         | 3.0                                    | 4.8                                    | 1.3                                    | 3.0                           | 3.5                      | 2.4               | 0.8006          | 0.6194          |
| APTT +dRVVT       | 3.0                                    | 2.1                                    | 0.4                                    | 1.8                           | 3.9                      | 0.6               | 0.4839          | 0.0511          |
| KCT +dRVVT        | 3.0                                    | 1.7                                    | 0.0                                    | 2.4                           | 4.0                      | 0.6               | 0.2196          | 0.0459*         |

*Statistically significant at 5% level.

Table 2. The prevalence of lupus anticoagulant in RFL in earlier studies.

| Previous studies | APTT (%) | KCT (%) | DRVVT (%) |
|------------------|----------|---------|-----------|
| Ria et al (17) (n= 300) | 1.0%     | 1.0%    | 6.7%      |
| Parke et al (19) (n=81)   | 4.9%     | ND      | ND        |
| Maclean et al (12) (n= 243) | 1.2%    | 1.2%    | 5.67%     |
| Infante-Rivard et al (23) (n=331) | 5.1% (Either APPT or dRVVT +PNP) | | |
| The current study (n=925) | 10.2%    | 10.5%   | 10.9%     |

In our study, the prevalence rates for lupus anticoagulant in 925 patients with recurrent fetal loss were not markedly different from that obtained in normal pregnancy, except for the prevalence with the dRVVT test, which was more than twice that in normal pregnancy (4.3% and 10.9% respectively). It is clear that in previous studies that employed the dRVVT test detected the presence of LA more frequently than the APTT and the KCT (Table 2). In the current study we found that the APTT, dRRVT and KCT tests had a prevalence comparable to LA in patients with RFL. However, when compared to the results obtained in normal pregnancy (Table 1), it is clear the dRVVT produced a remarkably higher rate of positive results than other tests. Of interest is that if only one or even two screening tests were performed a significant number of LA positive cases will be missed. This could make a difference in the wide variation in the prevalence of LA in normal pregnancy in this study (Table 1).
LUPUS ANTICOAGULANT AND RECURRENT FETAL LOSS

to the treating physician as to the possible etiology and further management of RFL. It is therefore advisable to routinely use the three tests (APTT, KCT and dRRVT) when screening for LA.

In the current study we followed test procedures, including the blood sampling technique and double centrifugation of the blood samples, detailed in the original assay techniques, while earlier studies have undertaken extensive modification of these assay techniques. This may account for the inter-laboratory variation in antiphospholipid antibody testing, a feature that has been highlighted recently. It is noteworthy that most of these earlier studies did not include the prevalence of LA in the healthy population or even in normal pregnancies, which is necessary to draw valid conclusions on the pathognomic role of these antiphospholipid antibodies in recurrent fetal loss. In one recent report the prevalence of LA in patients with RFL (n=331) was 5.1% while in controls (normal pregnancy, n=993) the prevalence was 3.8%. This led the authors to conclude that there is no justification for considering LA a risk factor in women with RFL. There is yet the possibility of the existence of ethnic differences in the prevalence of these antibodies, which was not yet reported, as far as we know. Such ethnic differences were documented in a variety of haemostatic studies and were closely related, for example, to the prevalence of ischaemic heart disease.

The mechanism of pregnancy loss associated with antiphospholipid antibodies (APAs) remains unclear, but has consistently been centered on placental thrombosis, as explained in a recent publication. On the other hand, placental thrombosis was not found in all RFL patients or in normal pregnant women with APAs. Also, RFL patients did not suffer overt systemic thrombotic disease. Nonetheless, the thrombotic mechanism gained more support from the advocates of antiplatelet (aspirin) and anticoagulant (heparin) therapy in the successful management of RFL patients.

In conclusion, the results of this large study have shown that if only one or even two screening tests were performed for the detection of LA, a significant number of LA-positive cases would be missed. This would make it difficult for treating physicians to make up their mind as to the possible etiology and further management of RFL. It is therefore advisable to routinely employ the three tests (APTT, KCT and dRRVT) when screening for LA.

Acknowledgments
We are grateful to Professor Adelusi A, Drs. Mustafa MS, Banu F, Aleem M for their help with patient selection and recruitment, and the facilitation of collection of data and to Dustin Kangave for undertaking statistical analysis, and to the technicians in the Coagulation Laboratory, College of Medicine (Messers Mohamed A. Hamid, Logman A. Gasmel Sid and Malou Casi) for their technical help and Mrs. Farah Charila her excellent secretarial help.

We would like to thank King Abdul Aziz City for Science and Technology (KACST) for the generous grant (Grant # AR-14-39) extended for this project.

This study was published in abstract form as: Al-Mishari AA, Gader A.M.A., Al Jabbari A W , Al Momen AK, Jad El Rab MO. We need to perform the three screening tests for lupus anticoagulant APTT, KCT and DRVVT to avoid missing positive cases. Thromb Haemostas- Suppl; July 2001; Abstract # CD 3257)

References
1. Kuttel WH. Recurrent pregnancy loss: an update. Curr Opin Obstet Gynecol. 1999;11:435-439.
2. Haris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radio-immunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211-1214.
3. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Am Intern Med. 1990;112:682-698.
4. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum. 1991;34:1231-1235.
5. Lockwood CJ, Romero R, Geinberg RF, Clyne LP, Coster R, Hobin JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipid antibodies in a general obstetric population. Am J Obstet Gynecol. 1989;161:369-373.
6. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A retrospective study. Ann Intern Med. 1994;120:470-475.
7. Branch DW. Antiphospholipid antibodies and reproductive outcome: the current state of affairs. J Reprod Immunol. 1998;38:75-87.
8. Kuttel WH, Rote NS, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome. Am J Reprod Immunol. 1999;41:133-152.
9. Petri M. The clinical syndrome associated with antiphospholipid antibodies (SLE) and in non-SLE disorders. Arthritis Rheum. 1992;35:505-507.
10. Guideline No. 17. The management of recurrent miscarriage. London: Royal College Obstetricians and Gynaecologists; 1998:1-10.
11. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol. 1999;106:102-107.
12. Maclean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol. 1994;101:103-106.
13. Brandt JT, Tripllett, DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus AnticoagulantAntiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185-1190.
14. Tripllett DA. The laboratory diagnosis of Lupus Anticoagulants. Fifth International Symposium on Antiphospholipid Antibodies. September 9-12, 1992. San Antonio, Texas. 1-13.
15. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol. 1978;40:143-151.
16. Thaagardan P, Pengo V, Sapio SS. The use of the dilute Russell Viper Venom Time for diagnosis of lupus anticoagulants. Blood. 1986;68:869-874.
17. Rai RS, Regan L, Clifford K, et al. Antiphospholipid antibodies and B2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Human Reprod. 1995;10:2001-2005.
18. Pattison NS, Chamley JW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol. 1993;100:909-913.

19. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheumat. 1991;34:1231-1235.

20. Peaceman AM, Silver RK, MacGregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol. 1992;166:1780-1787.

21. Haemostasis Committee of the "Societe Francaise De Biologie Clinique" Laboratory heterogeneity of the lupus anticoagulant: a multi centre study using different clotting assays on a panel of 78 samples. Thromb Res. 1992;66:3349-3364.

22. Schjettlein R, Wisloff F. An evaluation of two commercial test procedures for the detection of lupus anticoagulant. Am J Clin Pathol. 1995;103:108-111.

23. Infante-Rivard C, David M, Gauthier R, Rivard GE. Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med. 1991;325:1063-1066.

24. Gader A, Bahakim HM, Awadalla S, Malaika SS. Ethnic variations in the haemostatic system: Comparison between Arabs, Westerners (Europeans and Americans), Asians and Africans. Blood Coag Fibrin. 1995;5:537-542.

25. Meade TW, Sterling Y, Thompson SG et al. An international and interregional comparison of haemostatic variables in the study of ischaemic heart disease. Int J Epidemiol. 1986;15:331-336.

26. Cadavid A, Pena B, Garcia G, et al. Heparin plus aspirin as a "single" therapy for recurrent spontaneous abortion associated with both allo- and autoimmunity. Am J Reprod Immunol. 1999;41:271-278.